Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
作者:
发布时间
2013-11-20
- 浏览0

European urology
747-754页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文